Labcorp Holdings stock hits 52-week high at $264.04

Published 01/07/2025, 15:36
Labcorp Holdings stock hits 52-week high at $264.04

Labcorp Holdings Inc’s stock reached a 52-week high, peaking at $264.04. According to InvestingPro analysis, the company appears to be trading above its Fair Value, with analysts setting price targets between $248 and $300. This milestone reflects a significant upward trend for the company, as the stock has experienced a 30.09% increase over the past year. With a market capitalization of $22.07 billion and revenue growth of 7.13%, the rise in Labcorp’s stock price underscores investor confidence and the company’s robust performance in the healthcare sector. The company maintains a strong financial health score of "GOOD" according to InvestingPro metrics. This achievement comes amid broader market fluctuations, highlighting Labcorp’s resilience and strategic growth initiatives. For deeper insights into Labcorp’s performance and access to comprehensive Pro Research Reports covering 1,400+ top stocks, visit InvestingPro.

In other recent news, Labcorp Holdings Inc. reported its Q1 2025 earnings, showing a 5.3% increase in revenue to $3.3 billion, although this fell short of the forecasted $3.41 billion. Despite the revenue miss, Labcorp’s adjusted earnings per share (EPS) of $3.84 slightly exceeded expectations. Morgan Stanley (NYSE:MS) and Mizuho (NYSE:MFG) Securities have both adjusted their price targets for Labcorp, raising them to $283 and $274, respectively, while maintaining positive ratings. Analysts from these firms highlight Labcorp’s robust earnings visibility and durable demand trends. Additionally, Labcorp shareholders have approved new incentive plans, including the 2025 Omnibus Incentive Plan and Employee Stock Purchase Plan, indicating strong shareholder support for the company’s strategies. Labcorp also announced the development of new liver toxicity models in collaboration with Predictive Oncology, emphasizing its ongoing commitment to innovation. These developments reflect Labcorp’s strategic focus and resilience in a challenging macroeconomic environment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.